【摘要】 目的 探讨养血清脑颗粒对脑小血管病(CSVD)认知功能障碍(VCI)及血清β-淀粉样蛋白42(Aβ1-42)水平的影响.方法 将240例CSVD患者(MMSE评分<27分或MoCA评分<26分)分为常规治疗组、观察组(口服养血清脑颗粒),两组患者基础治疗相同，观察组连续口服养血清脑颗粒治疗3个月，观察3个月后两组MMSE及MoCA评分及血清Aβ1-42水平的变化，总时限为1 a,同时观察药物的不良反应.结果 3个月后，观察组MMSE、MoCA评分及血清Aβ1-42水平显著高于对照组(P<0.05);MMSE、MoCA评分与血清Aβ1-42水平呈负相关关系(r=-0.578,P<0.001;r=-0.709,P<0.001).结论 养血清脑颗粒能够改善脑小血管病(CSVD)认知功能障碍(VCI);血清Aβ1-42水平的改变可为VCI分子生物学指标的相关研究提供新思路.更多还原

【Abstract】 Objective To explore effects of Yangxue Qingnao Granule on cognitive function(VCI) and serum Aβ1-42 levels in cerebral small vascular disease(CSVD).Method A total of 240 patients with MOCA score<26 or MMSE score<27 were selected and divided into conventional treatment group and oral Yangxue Qingnao Granule group.The subjects of two groups were treated with the same basic treatment for 3 months continuously.The changes of MMSE and MOCA scale scores and serum Aβ1-42 level after 3 months were analyzed, with a total time of 1 year.The adverse reactions of drugs were also observed.Results After 3 months, MMSE,MOCA scores and serum Aβ1-42 levels in Yangxue Qingnao Granule group were significantly higher than those in control group(P<0.05).MMSE,MOCA scales were negative correlation with human serum Aβ1-42 levels(r=-0.578,P<0.001;r=-0.709,P<0.001).Conclusion Yangxue Qingnao Granule can improve VCI caused by CSVD.The changes of human serum Aβ1-42 level can provide a new idea for the study of molecular biological indicators for the detection of cognitive dysfunction.更多还原